Lazertinib (LuciLazer) 80mg | Lucius Laos Generic | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

分享
Product description

Generic Information: LuciLazer (Laos)

LuciLazer is a generic version of lazertinib produced by Lucius Pharmaceuticals (Lao) Co., Ltd., a manufacturer based in the Lao People's Democratic Republic that supplies affordable oncology medicines across South-East Asia. Each bottle carries sixty 80 mg tablets of the same active molecule found in the Korean and American originator brands, presented as a practical option for patients funding long-duration oral therapy themselves.

What Is Lazertinib (LuciLazer) Used For?

The product is used wherever lazertinib is clinically appropriate: advanced non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations, including disease that developed T790M resistance after first- or second-generation EGFR inhibitors. Under physician supervision it may be given as the oral partner of amivantamab combination protocols or managed as monotherapy according to local practice and the patient's treatment history.

How Does Lazertinib Work?

Lazertinib is a third-generation EGFR kinase blocker designed to silence mutant receptors selectively. Once swallowed, the tablet dissolves and the molecule binds irreversibly to the intracellular signalling switch of EGFR exon 19 deletion and L858R variants — and of the T790M resistance form — cutting the growth commands those receptors broadcast, while tolerating normal EGFR so that severe skin and gut toxicity is less frequent than with older drugs. Penetration of brain tissue supports control of intracranial lesions.

Indications

Appropriate candidates are adults with molecularly confirmed EGFR-mutated locally advanced or metastatic NSCLC. Before starting, oncologists confirm the mutation profile with tissue or liquid biopsy, review imaging and prior lines of therapy, and screen for conditions that complicate EGFR therapy such as lung fibrosis or uncontrolled cardiac disease; treatment continues under review until progression or limiting toxicity.

Dosage

The conventional adult dose is 240 mg per day taken as a single oral dose — three LuciLazer 80 mg tablets swallowed whole with water, with or without food. A sixty-tablet bottle therefore covers twenty days of standard therapy. The schedule is continuous, so refills are planned ahead; a missed tablet is taken once remembered unless the next dose is less than twelve hours away. Combination infusions, where prescribed, are scheduled separately at the treating hospital.

Side Effects

Expect the class-typical profile: papulopustular rash, paronychia around the nails, pruritus, diarrhoea, mouth soreness, diminished appetite and fatigue, with laboratory findings such as hypothyroidism or low serum magnesium appearing on routine panels. Serious but less common events — pneumonitis, blood clots and severe skin reactions — belong to the emergency-contact category. Supportive care (emollients, antiseptic nail care, antidiarrhoeals) and dose adjustments manage most effects.

Storage

LuciLazer tablets are stored dry at room temperature in tightly closed original containers, with no refrigeration or cold chain involved. GLT packs bottles in moisture-protected shippers and dispatches by ambient express from a Hong Kong-licensed facility, so the tablets arrive as stable as when they left the factory.

Why Choose LuciLazer Through GLT?

For self-funded patients the economics of daily oral therapy matter as much as the pharmacology: LuciLazer delivers the identical 80 mg lazertinib molecule at a generic budget, sourced by GLT from Lucius Pharmaceuticals with batch traceability and shipped from a Hong Kong-licensed facility. Institutions comparing cost tiers can position LuciLazer as the value option alongside the Korean, Chinese and American originator presentations GLT also supplies.

How to Order

To order LuciLazer (lazertinib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm bottle availability, shipping options and total landed cost to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is LuciLazer the same molecule as Lazcluze or Leclaza? Yes — identical 80 mg lazertinib tablets; LuciLazer is Lucius Pharmaceuticals' Lao-manufactured generic of the originator.

How long does one bottle last? Sixty 80 mg tablets equal twenty days at the standard three-tablet daily dose, so ongoing therapy needs roughly one and a half bottles per month.

Do generics of lazertinib meet quality standards? Lucius Pharmaceuticals manufactures under GMP with batch documentation; GLT supplies CoA and sourcing papers with every order for pharmacy verification.

Related Oncology Products

Mounjaro KwikPen(替尔泊肽)10–60mg/2.4mL 多剂量注射笔 | 礼来(美国)| GLT

Mounjaro KwikPen——礼来单患者多剂量注射笔,六种美国规格(10–60mg/2.4mL,各 4 剂)用于 2 型糖尿病。

奥氟格列隆/奥格列龙(OriYo)0.8–17.2mg 片剂 | 孟加拉仿制药 口服 GLP-1 | GLT

孟加拉国民制药(National Drug Co.)仿制奥氟格列隆,6 剂量递增用于体重管理

Rizonib(克唑替尼)250mg 胶囊 | 孟加拉 DIL 赛可瑞仿制药 用于 ALK+ 非小细胞肺癌 | GLT

Rizonib 250 由孟加拉通吉加济布尔的国际制药有限公司(DIL)生产——来自孟加拉的平价克唑替尼仿制药

Avabopa(阿伐曲泊帕)20mg*30片 | 老挝东盟制药 TLPH | GLT

Avabopa——老挝东盟制药(TLPH)阿伐曲泊帕 20mg,老挝注册号 07 L 0990/23

Tirzema(替尔泊肽)2.5/5/7.5mg/0.5mL 单剂量注射笔 | Incepta(孟加拉国)| GLT

Tirzema——Incepta Pharmaceuticals 替尔泊肽单剂量注射笔,三种官方规格(2.5/5/7.5mg/0.5mL),用于 2 型糖尿病和体重管理。

Zepbound(替尔泊肽)2.5–15mg/0.5mL 单剂量注射笔 | 礼来(美国)| GLT

Zepbound——礼来替尔泊肽单剂量注射笔,六种美国规格(2.5–15mg/0.5mL),用于慢性体重管理和阻塞性睡眠呼吸暂停。

Barinat(巴瑞替尼)4mg | 仿制 JAK1/JAK2 抑制剂 | Natco Pharma Limited | GLT

由 Natco Pharma Limited(印度)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

欣可平 XinKePing(阿伐曲泊帕)20mg*10片 | 南京恒生制药 | GLT

欣可平——南京恒生制药(济民可信集团)马来酸阿伐曲泊帕片,原料药与制剂一体化生产,中国大陆